The reason the options are not higher is probably due to the uncertainty regarding the effectiveness of Rida in Sarcoma. We expected an early filing but that did not happen. Easier to play the stock (short term) than the options right now.
They achieved outstanding early results with their second candidate 534 and that has been the catalyst for the current run.
Succeed trial outcome is not going to be as big a mover as the panel voting to approve a drug that was considered third in a 3 horse race. That was a huge binary event! Aria doesn't even own Rida, MRK does. So yes, to your point it will not move the pps % wise as much as Contrave getting a thumbs up and the options will reflect that.
News 
Market Data 
Discover 
